BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 30995926)

  • 1. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
    Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
    J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
    Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
    Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
    Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
    Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.
    Huang G; Yu L; Cooper LJ; Hollomon M; Huls H; Kleinerman ES
    Cancer Res; 2012 Jan; 72(1):271-81. PubMed ID: 22075555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
    Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.